

Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries

<https://marketpublishers.com/r/ED50CED8D6EEN.html>

Date: August 2011

Pages: 8

Price: US\$ 140.00 (Single User License)

ID: ED50CED8D6EEN

Abstracts

Eisai revenue is slated to drop following key products patent expiry i.e. Aricept and Aciphex (Pt. exp in Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval, Eisai has three late stage candidates E-2007/ perampanel, E7080/ lenvatinib and MORAb-003/ farletuzumab. However none of these will have enough potential to nullify the loss of Aricept and Aciphex even in their best case scenario.

Contents

COMPANIES MENTIONED

Eisai

I would like to order

Product name: Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries

Product link: <https://marketpublishers.com/r/ED50CED8D6EEN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ED50CED8D6EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970